𝔖 Bobbio Scriptorium

✦ LIBER ✦

Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?

✍ Scribed by Karen L Reckamp

Book ID: 117786072
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 103 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70157-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Attainment of complete/very good partial

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

✍ Steven P. Treon; Guang Yang; Christine Hanzis; Leukothea Ioakimidis; Sigitas J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

PCN16 MIXED TREATMENT COMPARISON OF BEVA

PCN16 MIXED TREATMENT COMPARISON OF BEVACIZUMAB-BASED THERAPIES RELATIVE TO DOUBLET-CHEMOTHERAPY COMBINATIONS TO ESTIMATE THE RELATIVE EFFICACY IN PROGRESSION-FREE SURVIVAL FOR TREATMENT OF FIRST-LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

✍ Y Yi; C Chouaid; A Vergnenegre; HG Bischoff; G Bergman; S Walzer; Z Philips 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Intermittent/alternated therapy with tam

Intermittent/alternated therapy with tamoxifen and medroxy-progesterone acetate prolongs time to resistance to tamoxifen without benefit for (progression free) survival in patients with advanced breast cancer. Results of an EORTC phase III study (trial 10863)

✍ L Beex; C Rose; H Mouridsen; J Jassem; M Nooy; J Estape; R Paridaens; M.J Piccar 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Phase II study of intravenous bevacizuma

Phase II study of intravenous bevacizumab (bev) and paclitaxel (pac), and intraperitoneal (ip) cisplatin (c), followed by bevacizumab (bev) maintenance, for advanced ovarian cancer: A report on progression-free survival (PFS) and toxicity

✍ L. Perry; G. Lanneau; J. Curiel; C. Mathews; K. Moxley; L. Landrum; K. Moore; J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 67 KB

6570 POSTER Results for progression-free

6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by similar populations and methodology

✍ Sandler, A.; Reck, M.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB